Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses.

9 10 Among them, its expression in LSCC is also highly significant, 11 with 68.5% of LSCC expressing higher levels of PD-L1 transcripts. 12 PD-L1 interaction with programmed cell death receptor 1 (PD-1) on T cells facilitates the transmission of immune inhibitory signals, leading to suppression of T-cell proliferation and aggregation.

also in 132,142 other papers